A lithium-ion battery that stores twice as much energy is a step closer to commercialization thanks to a deal with the U.K. home appliance company Dyson.
The startup Sakti3 announced today that it has signed a joint development agreement with Dyson, which makes vacuum cleaners and other appliances, to incorporate its batteries into new products. The companies didn’t say when those products will be available, but one could be a cordless vacuum cleaner. Dyson also announced a $15 million investment in the startup.
Sakti3 uses new materials and manufacturing techniques to achieve higher energy density. The company’s battery does away with the flammable liquid electrolyte used in conventional lithium-ion batteries, which makes it feasible to use a different set of high-energy storage materials (see “Solid-State Batteries” and “A Battery for Electronics That Lasts Twice as Long”).
The technology could have many applications, including electric vehicles, the range of which is limited by the size and cost of conventional batteries.
In a statement, Dyson founder and chief engineer James Dyson said, “Sakti3 has achieved leaps in performance which current battery technology simply can’t.”
Many battery startups have struggled to translate impressive lab results into products (see “Why We Don’t Have Battery Breakthroughs”), in part because their prototypes are custom-made, often using expensive manufacturing techniques that can’t easily be scaled up. Sakti3 makes its prototypes on standard manufacturing equipment, and this could help ensure that the technology, once perfected, can be commercialized.
Success isn’t a sure thing. Making a few prototypes might not translate to high yields in a factory, where conditions and raw materials can vary. But the partnership with Dyson, which has manufacturing experience and relatively deep pockets, could make the transition easier for Sakti3.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.